Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone and optimal supportive care with or without whole-brain radiotherapy for brain metastases from non-small cell lung cancer
ACTRN12607000264482Phase 3Terminated
- Sponsor
- Tanya Holt
- Start
- Mar 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in non-small cell lung cancer (NSCLC) and brain metastases (2 arms), sponsored by Tanya Holt. Primary endpoint: Patient-assessed quality adjusted life years (QALY). Started Mar 2007; status: terminated.
02
Drugs
dexamethasone
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ACTRN12607000264482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000264482.